Open Access Highly Accessed Research article

Caspofungin Use in Daily Clinical Practice for Treatment of Invasive Aspergillosis: Results of a Prospective Observational Registry

Johan Maertens1, Gerlinde Egerer2, Wan Shik Shin3, Dietmar Reichert4, Michael Stek5, Sheenu Chandwani6, Malathi Shivaprakash7*, Claudio Viscoli8 and the study team CAN-DO(IA)

Author Affiliations

1 UZ Gasthuisberg, Leuven, Belgium

2 Universitätsklinikum Heidelberg, Heidelberg, Germany

3 Department of Internal Medicine, The Catholic University of Korea College of Medicine, Seoul, Korea

4 Klinikum Oldenburg gGmbH, Oldenburg, Germany

5 ID Consultant Services, Ambler, PA, USA

6 UMDNJ- Robert Wood Johnson Medical School, Department of Family Medicine- Research Division, Somerset, NJ, USA

7 Merck & Co., Inc. Whitehouse Station, NJ, USA

8 San Martino University Hospital, Genova, Italy

For all author emails, please log on.

BMC Infectious Diseases 2010, 10:182  doi:10.1186/1471-2334-10-182

Published: 22 June 2010



A prospective observational registry assessed real world experience with caspofungin monotherapy or combination therapy for the initial or salvage treatment of proven or probable invasive aspergillosis (IA).


Data were collected from April 2006 to September 2007 for patients treated with caspofungin for a single episode of IA. Clinical effectiveness was categorized as favorable (complete or partial) or unfavorable (stable disease or failure) at the end of caspofungin therapy (EOCT).


Consecutive patients (n = 103) with proven or probable IA (per EORTC/MSG criteria) were identified from 11 countries. Malignancy (76.7%), neutropenia (64.1%), allogeneic hematopoietic stem cell transplantation (HSCT, 22.3%), solid organ transplantation (8.7%), autologous HSCT (4.9%), and HIV/AIDS (2.9%) were the most common underlying conditions. Most patients (84.5%) had pulmonary IA. Aspergillus fumigatus was the most frequently isolated species. The majority of patients received caspofungin monotherapy (82.5%) primarily as salvage therapy (82.4%). The main reason for switching to salvage therapy was clinical failure of the first-line therapy (69%). A favorable response at EOCT was seen in 56.4% (57/101) of patients overall, including 56.5% (48/85) and 56.3% (9/16) of patients receiving caspofungin monotherapy and combination therapy, respectively. Favorable response rates in clinically relevant subgroups were: malignancy, 51.9% (41/79); allogeneic HSCT, 56.5% (13/23); and neutropenia at time of hospitalization, 53.0% (35/66). There was a 72.3% (73/101) survival at 7 days after EOCT. Serious adverse events related to caspofungin were reported in 4 cases (3.9%); 3 patients (2.9%) discontinued treatment due to an adverse event related to caspofungin.


Caspofungin was both effective and well tolerated among high-risk patient groups such as those with neutropenia and active malignancies.